Is ABT or BMY cheaper?

On trailing earnings, BMY is cheaper: ABT trades at a 24.56 P/E and BMY at 16.05.

Which has grown faster, ABT or BMY?

Over the past five years, ABT grew revenue faster — ABT at a 3.87% CAGR versus BMY at 2.52%.

Does ABT or BMY pay a bigger dividend?

ABT yields 2.77% and BMY yields 4.38% based on trailing dividends and the latest price.

Is ABT or BMY more profitable?

BMY runs the higher net margin — ABT at 13.91% versus BMY at 15.01%.

Which has been the better investment, ABT or BMY?

Over the past 10-year, ABT delivered the higher annualized total return — ABT at 10.72% versus BMY at 1.08%. Past performance doesn't predict future results.

Abbott Laboratories (ABT) vs Bristol-Myers Squibb Company (BMY)

BMY leads on 14 of 17 compared metrics.

A side-by-side comparison of Abbott Laboratories and Bristol-Myers Squibb Company across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 14, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).

Bristol-Myers Squibb Company

$116.66B

$57.13Healthcare

Total return — ABT vs BMY

growth of $100 · last 30y

ABT +814.7%BMY +171.1%ABT compounded faster

ABT BMY

ABT vs BMY: by the numbers

•ABT is the larger company ($153.59B vs $116.66B market cap).
•BMY trades at the lower earnings multiple (16.05 vs 24.56 P/E).
•BMY converts more revenue to profit (15.01% vs 13.91% net margin).
•ABT grew revenue faster over the past five years (3.87% vs 2.52% CAGR).
•BMY pays the higher dividend yield (4.38% vs 2.77%).

Which is better, ABT or BMY?

Metric tally: ABT 3 · BMY 14

It depends on what you're optimizing for:

ValueBMY(lower P/E)

GrowthABT(faster 5Y revenue CAGR)

IncomeBMY(higher dividend yield)

QualityBMY(higher ROIC)

Valuation

Metric	ABT	BMY
P/E ratio	24.56	16.05●
Forward P/E	14.56	9.31●
P/S ratio	3.41	2.41●
P/B ratio	2.96●	5.82
PEG ratio	2.99	1.71●
EV / EBITDA	17.30	11.03●
FCF yield	4.79%	10.20%●

Profitability

Metric	ABT	BMY
Gross margin	56.38%	68.75%●
Operating margin	18.17%	25.67%●
Net margin	13.91%	15.01%●
ROE	12.06%	36.25%●
ROIC	8.43%	13.90%●

Dividends

Metric	ABT	BMY
Dividend yield	2.77%	4.38%●
Payout ratio	65.24%	72.25%

Growth (annualized)

Metric	ABT	BMY
Revenue CAGR (5Y)	3.87%●	2.52%
EPS CAGR (5Y)	8.22%	9.38%●
FCF CAGR (5Y)	-0.61%●	-2.50%
Total return CAGR (5Y)	-2.49%	0.74%●

Frequently asked

Which is better, ABT or BMY?: It depends on your goal. value: BMY (lower P/E); growth: ABT (faster 5Y revenue CAGR); income: BMY (higher dividend yield); quality: BMY (higher ROIC). Across all compared metrics, BMY leads 14 to 3.
Is ABT or BMY cheaper?: On trailing earnings, BMY is cheaper: ABT trades at a 24.56 P/E and BMY at 16.05.
Which has grown faster, ABT or BMY?: Over the past five years, ABT grew revenue faster — ABT at a 3.87% CAGR versus BMY at 2.52%.
Does ABT or BMY pay a bigger dividend?: ABT yields 2.77% and BMY yields 4.38% based on trailing dividends and the latest price.
Is ABT or BMY more profitable?: BMY runs the higher net margin — ABT at 13.91% versus BMY at 15.01%.
Which has been the better investment, ABT or BMY?: Over the past 10-year, ABT delivered the higher annualized total return — ABT at 10.72% versus BMY at 1.08%. Past performance doesn't predict future results.

Go deeper

Full ABT analysis Full BMY analysis Interactive comparison tool

Dig into the metrics

Abbott Laboratories P/E ratio Bristol-Myers Squibb P/E ratio Abbott Laboratories dividend yield Bristol-Myers Squibb dividend yield Abbott Laboratories ROE Bristol-Myers Squibb ROE Abbott Laboratories operating margin Bristol-Myers Squibb operating margin Abbott Laboratories revenue growth Bristol-Myers Squibb revenue growth Abbott Laboratories free cash flow Bristol-Myers Squibb free cash flow

Abbott Laboratories & Bristol-Myers Squibb appear in these rankings

Highest Dividend Yield Stocks Dividend Aristocrats Highest ROE Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 14, 2026.